Shaker Itani
Infectious Disease · Las Vegas, NVNPI 1538193826
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,868 of the $52,043 with a category attached, or 80.4%. Melinta Therapeutics, LLC accounts for 92.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $31,515 and has fallen 99.7% since, to $85 in 2025. Among infectious disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $268.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$48K
- Insmed, Inc.$2K
- Cipla USA Inc.$377
- AbbVie$303
- Cumberland Pharmaceuticals, Inc.$192
- Merck$176
- plus $418 from 11 others
What the payments were for
- Speaking & faculty fees$41,86880%
- Travel & lodging$3,9848%
- Food & beverage$6,03412%
- Education$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 86 | $48,235 |
| Insmed, Inc. | 65 | $2,342 |
| Cipla USA Inc. | 1 | $377 |
| AbbVie(2 entities) | 10 | $303 |
| Cumberland Pharmaceuticals, Inc. | 5 | $192 |
| Merck | 6 | $176 |
| Astellas Pharma US Inc | 4 | $100 |
| Viiv Healthcare Company | 5 | $99 |
| Nabriva Therapeutics, PLC | 3 | $56 |
| Shionogi Inc | 2 | $38 |
| Vertex | 1 | $34 |
| Theratechnologies Inc. | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Oxford Immunotec USA Inc | 1 | $14 |
| Napo Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,043 in reported general payments places this provider in the 95th percentile of 65 infectious disease providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CeftriaxoneCeftriaxone Sodium | 12 | $208 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$588K
- Dhiresh JoshiLas Vegas$96K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
- Ricardo Cedeno-MendozaLas Vegas$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.